Regorafenib Gives Colorectal Cancer Patients More Time

(MedPage Today) — The investigational drug regorafenib extended overall survival in patients with treatment-refractory advanced colorectal cancer by 1.4 months in a phase III trial, according to its manufacturer.

Post a Comment

Comments are closed.